One allele's loss is another's gain: Alterations of NKX2-8 in non-small cell lung cancer

Por Neal, Joel W., Shaw, Alice
Publicado em 2010

Novel Targets in Non-Small Cell Lung Cancer: ROS1 and RET Fusions

Por Gainor, Justin F., Shaw, Alice T.
Publicado em 2013

Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

Por Gainor, Justin F., Shaw, Alice T.
Publicado em 2013

Molecular Pathways: Resistance to Kinase Inhibitors and Implications for Therapeutic Strategies

Por Lovly, Christine M., Shaw, Alice T.
Publicado em 2014

ALK in Lung Cancer: Past, Present, and Future

Por Shaw, Alice T., Engelman, Jeffrey A.
Publicado em 2013

ALK Inhibitors in Non–Small Cell Lung Cancer: Crizotinib and Beyond

Por Awad, Mark M., Shaw, Alice T.
Publicado em 2014

Screening for ALK Rearrangements in Lung Cancer: Time for a New Generation of Diagnostics?

Por Dagogo-Jack, Ibiayi, Shaw, Alice T.
Publicado no Oncologist (2016)

Resisting Resistance: Targeted Therapies in Lung Cancer

Por Lin, Jessica J., Shaw, Alice T.
Publicado no Trends Cancer (2016)

Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine

Por Katayama, Ryohei, Lovly, Christine M., Shaw, Alice T.
Publicado no Clin Cancer Res (2015)

Targeted inhibition in tumors with ALK dependency

Por Kwak, Eunice L, Clark, Jeffrey W, Shaw, Alice T
Publicado no Lung Cancer (Auckl) (2013)

Targeting ALK: Precision Medicine Takes On Drug Resistance

Por Lin, Jessica J., Riely, Gregory J., Shaw, Alice T.
Publicado no Cancer Discov (2017)

Structural Constraints on Human Immunodeficiency Virus Type 1 Nef Function

Por Raney, Alexa, Shaw, Alice Y., Foster, John L., Garcia, J. Victor
Publicado em 2007

Tyrosine kinase gene rearrangements in epithelial malignancies

Por Shaw, Alice T., Hsu, Peggy P., Awad, Mark M., Engelman, Jeffrey A.
Publicado em 2013

Integration of Stereotactic Body Radiation Therapy With Tyrosine Kinase Inhibitors in Stage IV Oncogene-Driven Lung Cancer

Por Campo, Meghan, Al-Halabi, Hani, Khandekar, Melin, Shaw, Alice T., Sequist, Lecia V., Willers, Henning
Publicado no Oncologist (2016)

Cabozantinib overcomes crizotinib resistance in ROS1 fusion positive cancer

Por Katayama, Ryohei, Kobayashi, Yuka, Friboulet, Luc, Lockerman, Elizabeth. L., Koike, Sumie, Shaw, Alice T., Engelman, Jeffrey A., Fujita, Naoya
Publicado no Clin Cancer Res (2014)

Alectinib Salvages CNS Relapses in ALK-Positive Lung Cancer Patients Previously Treated with Crizotinib and Ceritinib

Por Gainor, Justin F., Sherman, Carol A., Willoughby, Kathryn, Logan, Jennifer, Kennedy, Elizabeth, Brastianos, Priscilla K., Chi, Andrew S., Shaw, Alice T.
Publicado no J Thorac Oncol (2015)

Alectinib Dose Escalation Re-induces Central Nervous System Responses in ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients Relapsing on Standard Dose Alectinib

Por Gainor, Justin F., Chi, Andrew S., Logan, Jennifer, Hu, Ranliang, Oh, Kevin S., Brastianos, Priscilla K., Shih, Helen A., Shaw, Alice T.
Publicado no J Thorac Oncol (2015)

Ceritinib in patients with advanced anaplastic lymphoma kinase–rearranged anaplastic large-cell lymphoma

Por Richly, Heike, Kim, Tae Min, Schuler, Martin, Kim, Dong-Wan, Harrison, Simon J., Shaw, Alice T., Boral, Anthony L., Yovine, Alejandro, Solomon, Benjamin
Publicado no Blood (2015)

Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress

Por Shaw, Alice T., Winslow, Monte M., Magendantz, Margaret, Ouyang, Chensi, Dowdle, James, Subramanian, Aravind, Lewis, Timothy A., Maglathin, Rebecca L., Tolliday, Nicola, Jacks, Tyler
Publicado em 2011

Significance of targeted therapy and genetic alterations in EGFR, ALK, or KRAS on survival in patients with non–small cell lung cancer treated with radiotherapy for brain metastase...

Por Mak, Kimberley S., Gainor, Justin F., Niemierko, Andrzej, Oh, Kevin S., Willers, Henning, Choi, Noah C., Loeffler, Jay S., Sequist, Lecia V., Shaw, Alice T., Shih, Helen A.
Publicado no Neuro Oncol (2015)